about
PEGylated Adenoviruses: From Mice to MonkeysTargeted Delivery Systems for Molecular Therapy in Skeletal DisordersImproving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?In-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphomaPEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.Nanoparticle Uptake: The Phagocyte ProblemEmerging PEGylated drugs.IL11 antagonist inhibits uterine stromal differentiation, causing pregnancy failure in mice.Polysaccharide-modified synthetic polymeric biomaterials.Development of disposable PDMS micro cell culture analog devices with photopolymerizable hydrogel encapsulating living cells.Functionalized single-walled carbon nanotubes containing traces of iron as new negative MRI contrast agents for in vivo imaging.In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen.Optical imaging in vivo with a focus on paediatric disease: technical progress, current preclinical and clinical applications and future perspectivesOptimal structural design of mannosylated nanocarriers for macrophage targeting.Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat.Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug.Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo.In Vitro Study of Surface Modified Poly(ethylene glycol)-Impregnated Sintered Bovine Bone Scaffolds on Human Fibroblast Cells.The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes.Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.IgG Fab fragments forming bivalent complexes by a conformational mechanism that is reversible by osmolytes.Novel delivery systems for interferons.Sortase-catalyzed initiator attachment enables high yield growth of a stealth polymer from the C terminus of a protein.Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.Targeting liposomes toward novel pediatric anticancer therapeutics.Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.Product development issues for PEGylated proteins.Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking.RETRACTED: Recent trends of polymer mediated liposomal gene delivery system.Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier.Nanomedicine strategies for hematological malignancies: what is next?Sequence-defined polymers for the delivery of oligonucleotides.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Side-chain cysteine-functionalized poly(2-oxazoline)s for multiple peptide conjugation by native chemical ligation.Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery.
P2860
Q24635276-B61C13D7-F6CC-40F0-B8A2-7D3AB44F3BC3Q26752158-4F58D2AD-BD27-4BA4-BB1E-CE21EF75B5BAQ26999332-65E4F78D-B039-466D-A246-592093080E57Q27305229-97ECE505-A9FA-4B3A-9BF2-7A27668AA39EQ27691352-419F4F5D-A90C-4B79-A2F7-08023746EE7EQ28395287-646A5711-0A49-4722-8DF3-534A5CB89120Q33447691-BA28B9BA-1E49-4DA5-94B4-2E600E4EC9D6Q33770696-8BA7C387-7F8A-4A4C-A681-59F81F945382Q33978402-BA47033E-B6B7-4445-A854-ACC666673267Q34097011-DD611939-1612-45C5-8E2D-BBD021709900Q34204245-1B953C31-BA64-431F-8E20-4F837977F73DQ34444552-82772A55-1B93-4132-98D8-D30263BAEDBDQ34544842-D21F1279-4A7C-4F22-A838-4CE8AC69EA5FQ34623115-00FDE856-6223-4FD9-AA05-76E999675690Q34704754-8F68490B-FC2C-494E-9ABD-ABE5C2FA0D2DQ34764424-567DE015-10E7-485D-9F62-E0CDBA9C9FDBQ34774678-EE6D659E-549D-4ECF-90E9-492C2D297206Q35136562-3B9B106B-399D-4D6D-94E0-7507AEB2110DQ35571965-492F5786-8800-4834-B04E-18AA8C86D27DQ35580089-C00DFB3C-986D-4D29-899B-B4B7801C867EQ35669424-0D463C95-D1A5-4901-802C-B27A83AEB7E6Q36125194-1702A237-A338-4E43-B457-E9B377B24E1CQ36466773-55FFDE78-1D77-43E6-BAB6-E569F997AFEDQ36937971-C112B611-8BC7-452A-8592-CE68D03090C8Q37125527-A134E760-AB59-4411-8785-C49E11B80C61Q37623841-2C9C9769-5667-4FE6-9595-DFF8DF93A443Q37634856-8AAC9E64-69F8-435D-B7D5-EC552167D4EAQ37684734-6F9C84FA-054A-4F3A-86EE-E7CAAA70FCF7Q37721844-56B8CE0D-0357-4FB4-8AB5-208F307E26EDQ37790702-D025C0D7-97DC-46ED-8D79-D6667F9095C7Q37955222-E77D665F-E401-4915-BA31-643844A537B7Q38036746-B36E8021-15F4-4E1C-932D-7A9E8D4AA4A1Q38047267-AFA93FD0-ACBE-4416-A1C1-9F087E3EB966Q38253654-C74FEC46-F676-49E8-BB73-6D3255F1D019Q38269392-E39B11C6-4269-4061-BB48-BB15AB6CF632Q38270098-4B8AD352-FE34-4E12-A90C-F6600F88622EQ38298812-EC8F2CE5-5FF0-480E-BBE3-05E94975BCE1Q38574414-D7E54D2F-7AEF-4361-BC95-C091E1F6E58FQ38904846-605F3C52-5626-4CF2-AC9D-7E88E4B546EEQ38955588-59F8CBD1-BFAB-49FD-93E4-FE0D919ACFCA
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacokinetic consequences of pegylation.
@ast
Pharmacokinetic consequences of pegylation.
@en
type
label
Pharmacokinetic consequences of pegylation.
@ast
Pharmacokinetic consequences of pegylation.
@en
prefLabel
Pharmacokinetic consequences of pegylation.
@ast
Pharmacokinetic consequences of pegylation.
@en
P2860
P1433
P1476
Pharmacokinetic consequences of pegylation.
@en
P2093
Amir Azadi
Pedram Rafiei
P2860
P304
P356
10.1080/10717540600814402
P407
P577
2006-11-01T00:00:00Z